TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $22.00

TG Therapeutics (NASDAQ:TGTX) had its target price lifted by The Goldman Sachs Group from $20.00 to $22.00 in a report released on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on TGTX. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, TD Cowen began coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $27.90 on Tuesday. TG Therapeutics has a one year low of $9.81 and a one year high of $28.41. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -278.97 and a beta of 2.19. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. The business’s 50 day moving average price is $23.73 and its 200 day moving average price is $20.36.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.65% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter in the previous year, the business posted $0.73 EPS. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. On average, research analysts predict that TG Therapeutics will post 0.13 EPS for the current year.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently modified their holdings of the company. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares in the last quarter. Quarry LP grew its stake in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 503 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares in the last quarter. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,092 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.